8-K: Atossa Therapeutics Advances Breast Cancer Drug

Atossa Therapeutics reports positive FDA feedback and strong Phase 2 clinical results for its lead breast cancer drug, (Z)-endoxifen, paving the way for a Q4 2025 IND submission.

Summary

• Atossa Therapeutics announced its financial results for the second quarter ended June 30, 2025, alongside a corporate update on its (Z)-endoxifen program.
• The U.S. Food and Drug Administration (FDA) provided highly constructive written feedback, supporting the proposed dose optimization trial for (Z)-endoxifen in ER+/HER2metastatic breast cancer.
• The FDA agreed that existing clinical and nonclinical data are sufficient to initiate the monotherapy arm (Part A) of the study and confirmed no additional general toxicity or neurotoxicity studies are required.
• Full results from the Phase 2 pilot within the I-SPY 2 trial for monotherapy with low-dose 10 mg (Z)-endoxifen showed 95% of subjects completed at least 75% of planned dosing.
• In the I-SPY 2 monotherapy trial, median Ki67 dropped from 10.5% at baseline to 5% by Week 3, with 65% achieving Ki67 ≤ 10%.
• Median functional tumor volume decreased by 77.7% and longest tumor diameter dropped by 36.8% from baseline to surgery in the I-SPY 2 monotherapy trial.
• Safety in the I-SPY 2 monotherapy trial was favorable, with predominantly Grade 1 adverse events and no Grade 4 or 5 events reported.
• Patient recruitment for the I-SPY 2 combination therapy pilot (40 mg (Z)-endoxifen and Eli Lilly's abemaciclib) is proceeding faster than anticipated, with 41 patients initiated as of July 29, 2025.
• Total operating expenses increased to $9.0 million for Q2 2025, up from $7.1 million in Q2 2024, primarily due to increased Research & Development (R&D) spend.
• R&D expenses increased by 55% to $5.5 million in Q2 2025, driven by higher clinical and non-clinical trial costs and increased headcount.
• Net loss for Q2 2025 was $8.4 million, compared to $6.0 million for Q2 2024.
• Cash and cash equivalents were $57.86 million as of June 30, 2025, down from $71.08 million at December 31, 2024.
• A new U.S. Patent No. 12,281,056 was issued in mid-May 2025, covering enteric oral formulations of (Z)-endoxifen.
• The company has chosen not to utilize its ATM facility at recent share price levels, believing they significantly undervalue the company's potential.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant clinical and regulatory advancements, particularly the constructive FDA feedback clearing the path for IND submission and strong Phase 2 efficacy data. While financial losses increased, this is typical for a clinical-stage biotech, and the company explicitly stated it is not utilizing its ATM facility, indicating confidence in its current financial position and future valuation. The patent challenges are noted but deemed manageable by management.

Positives

• Received highly constructive written feedback from the FDA, supporting the proposed dose optimization trial for (Z)-endoxifen in metastatic breast cancer.
• FDA agreed that existing clinical and nonclinical data are sufficient to initiate the monotherapy arm of the study and confirmed no additional general toxicity or neurotoxicity studies are required.
• I-SPY 2 monotherapy trial achieved its primary endpoint, with 95% of subjects completing at least 75% of planned dosing.
• Significant reduction in Ki67 (from 10.5% to 5% median) and tumor volume (77.7% decrease) observed in I-SPY 2 monotherapy trial, indicating strong efficacy.
• Favorable safety profile in I-SPY 2 monotherapy trial, with predominantly Grade 1 adverse events and no Grade 4 or 5 events.
• Faster-than-anticipated patient recruitment for the I-SPY 2 combination therapy pilot.
• Issuance of new U.S. Patent No. 12,281,056, strengthening the intellectual property portfolio for (Z)-endoxifen formulations.
• Company maintains a strong balance sheet, positioning it well for upcoming clinical milestones.
• Management's decision not to utilize the ATM facility at current share price levels indicates confidence in higher future valuation.

Negatives

• Increased total operating expenses to $9.0 million in Q2 2025 from $7.1 million in Q2 2024, leading to higher cash burn.
• Net loss widened to $8.4 million in Q2 2025 from $6.0 million in Q2 2024.
• Cash and cash equivalents decreased by $13.22 million from December 31, 2024, to June 30, 2025.
• Interest income decreased due to lower average balance invested in money market accounts.
• Two of the company's patents (U.S. Patent Nos. 11,261,151 and 12,071,391) are subject to post-grant challenges, which may result in modification or invalidation of certain claims.

Risks

• The company's ability to obtain patent coverage for its product candidates, as two patents are currently subject to post-grant challenges that may lead to modification or invalidation of claims.
• Macroeconomic conditions and increasing geopolitical instability could impact operations.
• Any variation between interim or preliminary and final clinical results or analysis could affect drug development.
• Actions and inactions by the FDA and foreign regulatory bodies, including the outcome or timing of regulatory approvals needed to continue planned trials.
• The ability to satisfy regulatory requirements and maintain compliance with Nasdaq listing requirements.
• The success, costs, and timing of development activities, including the ability to successfully initiate or complete clinical trials.
• Anticipated rate of patient enrollment in clinical trials may not be met.
• Ability to contract with third-parties and their ability to perform adequately.
• Ability to successfully defend litigation and other similar complaints and to establish and maintain intellectual property rights covering products.
• Whether clinical trials will meet their objectives.
• Future financial performance, expense levels, and capital sources, including the ability to raise capital.
• Ability to attract and retain key personnel.
• Anticipated working capital needs and the sufficiency of cash reserves.

Future Outlook

The company is focused on executing its breast cancer development strategy for (Z)-endoxifen. Key upcoming deliverables include announcing the Contract Research Organization (CRO) for the metastatic dose ranging study, disclosing the dose-ranging trial design, and targeting an Investigational New Drug (IND) application submission in Q4 2025. The company also plans to advance enrollment and data generation from ongoing Phase 2 trials and work with the FDA on regulatory strategies for breast cancer indications beyond metastatic breast cancer, including adjuvant settings, DCIS, and prevention in high-risk women.

Management Comments

• "Atossa continues to make meaningful and measurable progress across our pipeline, underscored by recent, highly constructive interactions with the FDA that further support our (Z)-endoxifen development strategy in metastatic breast cancer."
• "With a strong balance sheet, we believe we are well-positioned to execute on our planned upcoming IND submission and advance our metastatic clinical program toward key value-creating milestones."
• "We remain disciplined in our capital strategy and have deliberately chosen not to utilize our ATM facility at recent share price levels, which we believe significantly undervalue the true potential of our Company."
• "As we progress toward multiple upcoming potential catalysts, we are confident that our focused execution, scientific rigor, and unwavering commitment to patients will demonstrate the substantial intrinsic value of Atossa and position (Z)-endoxifen to make a meaningful impact in the treatment of breast cancer."

Industry Context

The biopharmaceutical industry, particularly in oncology, is highly competitive and driven by clinical trial success and regulatory approvals. Atossa's focus on (Z)-endoxifen, a Selective Estrogen Receptor Modulator (SERM), positions it within the endocrine therapy segment for breast cancer. The positive FDA feedback and progress towards an IND application for metastatic breast cancer are critical steps in a field urgently needing novel therapeutic options, especially for patients who have developed resistance to existing endocrine therapies. The company's strategy to explore combination therapies with standard-of-care agents like CDK4/6 inhibitors (e.g., Eli Lilly's abemaciclib) aligns with current industry trends towards combination regimens to improve patient outcomes.

Comparison to Industry Standards

• The I-SPY 2 trial's observed median Ki67 drop from 10.5% to 5% by Week 3, with 65% achieving Ki67 ≤ 10%, compares favorably to the POETIC trial. The POETIC trial, a large Phase 3 study, demonstrated that women with ER+/HER2breast cancer whose Ki-67 levels fell to ≤10% after two weeks of neoadjuvant aromatase inhibitor therapy had a 5-year recurrence rate of 8.4%, significantly lower than the 21.5% for those whose Ki-67 remained above 10%. This suggests (Z)-endoxifen's early impact on Ki67 aligns with a strong prognostic indicator for reduced recurrence.
• The company's plan to explore combination therapy arms with standard-of-care agents such as CDK4/6 inhibitors (e.g., Eli Lilly's abemaciclib), PI3K inhibitors, mTOR inhibitors, and capecitabine, is consistent with established treatment paradigms in metastatic breast cancer, aiming to enhance efficacy and overcome resistance mechanisms.

Legal Proceedings

• Two of the company's patents (U.S. Patent Nos. 11,261,151 and 12,071,391) are currently the subject of post-grant challenges, which may result in modification or invalidation of certain patent claims.

Stakeholder Impact

• **Shareholders**: Positive clinical and regulatory news, especially FDA feedback and strong Phase 2 data, could lead to increased share price and long-term value. Increased operating expenses and net loss indicate continued cash burn, but the decision not to use the ATM facility suggests management believes current share prices undervalue the company.
• **Patients**: Progress in (Z)-endoxifen development, particularly for metastatic breast cancer, offers potential for new and effective treatment options, especially for those with resistance to existing therapies.
• **Employees**: Continued progress in clinical development and a strong balance sheet provide stability and potential for growth within the company.
• **Regulatory Authorities (FDA)**: The constructive feedback and alignment on development strategy indicate a collaborative relationship and clear regulatory path for (Z)-endoxifen.

Next Steps

• Announce Contract Research Organization (CRO) selected to execute the metastatic dose ranging study.
• Disclose dose-ranging trial design, including specifics on patient selection criteria and combination treatment backbone.
• Targeting Investigational New Drug (IND) application submission in Q4 2025.
• Advance enrollment and data generation from ongoing Phase 2 trials.
• Work with the FDA on regulatory strategies for breast cancer indications beyond metastatic breast cancer, including adjuvant setting, DCIS, and reducing incidence in high-risk women.

Key Dates

Recommendation

The filing presents highly significant positive developments for Atossa Therapeutics. The constructive FDA feedback, clearing the path for an IND submission for (Z)-endoxifen in metastatic breast cancer without requiring additional toxicity studies, de-risks a major regulatory hurdle. Coupled with compelling Phase 2 data from the I-SPY 2 trial, showing significant Ki67 reduction and tumor volume decrease with a favorable safety profile, the clinical program demonstrates strong potential. While the company experienced increased operating expenses and net loss, this is expected for a clinical-stage biotech advancing its pipeline. The explicit decision not to utilize the ATM facility at current share price levels signals management's belief in substantial undervaluation. These factors collectively point to a strong upside potential as the company progresses towards key value-creating milestones, making it a strong buy for investors with a long-term horizon.

Keywords

Breast Cancer, Z-endoxifen, FDA, Clinical Trials, Biopharmaceutical, Oncology, Metastatic Breast Cancer, ER+/HER2-, IND Submission, I-SPY 2, Ki67, SERM, Patent, Drug Development, Nasdaq